Синдром раздраженного кишечника римский критерий

• Архив журнала
  /
• 2008
  /
• №10

Синдром раздраженного кишечника: путь к Римским критериям III

Румянцев В.Г.

В статье представлена хронология развития представлений о функциональных расстройствах кишечника и наиболее часто встречающейся в клинической практике форме заболевания – синдроме раздраженного кишечника (СРК). Приведены изменения, внесенные международными экспертами Римской организации, в определение болезни, классификацию, рекомендации по диагностике и лечению СРК, основанные на принципах доказательной медицины.

Литература

1. Atkinson W, Sheldon TA, Shaath N, et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomized controlled trial. Gut 2004;53:1459–64.
2. Barbara G, Stanghellini V, DeGiorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126:693–702.
3. Bayless TM. Inflammatory bowel disease and irritable bowel syndrome. Med Clin N Am 1990;49:21–28.
4. Camilleri M, Atanasova E, Carison PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123:425–32.
5. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122:1778–83.
6. Chang L, Berman S, Mayer EA, et al. Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol 2003;98:1354–61.
7. Chaudhary NA, Truelove SC. The irritable colon syndrome. Q J Med 1962;31:307–22.
8. Christensen J. Heraclides or the physician. Gastroenterol Int 1990;3:45–48.
9. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15:79–86.
10. Cumming W. Electro-galvanism in a peculiar affliction on the mucous membrane of the bowels. London Med Gazette 1849;NS9:969–73.
11. Dalton CB, Drossman DA, Hathaway MD, et al. Perceptions of physicians and patients with organic and functional gastroenterological diagnoses. J Clin Gastroenterol Hepatol 2004; 2:121–26.
12. Delgado-Aros S, Camilleri M. Visceral hypersensitivity 2. J Clin Gastroenterol 2005;39: 194–203.
13. Drossman DA. Psychosocial and psychophysiologic mechanisms in GI illness. In: Kirsner J.B.,ed. The growth of gastroenterologic knowledge in the 20th century. Philadelphia: Lea & Febiger 1993:41–432.
14. Drossman DA. Presedential address: gastrointestinal illness and biopsychosocial model. Psychosom Med 1998;60:258–67.
15. Drossman DA. Challenges in the physician-patient relationship: feeling “drained”. Gastroenterology 2001;121:1037–38.
16. Drossman DA. Functional GI disorders: what’s in a name? Gastroenterology 2005;128:1771–72.
17. Drossman DA. Brain imaging and its implications for studying centrally targeted treatments in IBS: a primer for gastroenterologists. Gut 2005;54:569–73.
18. Drossman DA, Funch-Jensen P, Janssens J, et al. Identification of subgroups of functional bowel disorders. Gastroenterol Int 1990;3:159–72.
19. Drossman DA, Richter JE, Talley NJ, et al. Functional gastrointestinal disorders. Boston: Little, Brown 1994.
20. Drossman DA, Corazziari E, Talley NJ, et al. Rome II: a multinational consensus document on functional gastrointestinal disorders 1999.
21. Drossman DA, Whitehead WE, Toner BB, et al. What determines severity among patients with painful functional disorders? Am J Gastroenterology 2000;95:974–80.
22. Drossman DA, Camilleri M, mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108–31.
23. Drossman DA, Ringel Y, Vogt B, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe IBS. Gastroenterology 2003;124:754–61.
24. Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome: defining an altemator. Gastroenterology 2005;128:580–89.
25. Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in post-infections IBS. Gastroenterology 2003;125:1651–59.
26. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349–57.
27. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977; 196:129–36.
28. Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry 1980; 137:535–44.
29. Evans B, Clark W, Moore D, et al. Tegaserod foe the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004; 1:CD003960.
30. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome 2. J Clin Gastroenterol 2005; 39:184–93.
31. Gonsalkorale WM, Perrey C, Pravica V, et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52:91–93.
32. Gorard DA, Libby GW, Farthing MJG. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40:86–95.
33. Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005;100:1174–84.
34. Gwee K-A. Irritable bowel syndrome in developing countries – a disorder of civilization or colonization? Neurogastroenterol Motil 2005; 17:317–24.
35. Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1 beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523–26.
36. Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997;11:553–59.
37. Hale-White W. Colitis. Lancet 1895;1:537.
38. Heaton KW, Ghosh S, Braddon FEM. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 1991;32:73–79.
39. Heitkemper M, Carter E, Ameen V, et al. Women with irritable bowel syndrome: differences in patients’ and physicians’ perceptions. Gastroenterol Nurs 2002;25:192–200.
40. Hobday DI, Aziz Q, Thacker N, et al. A study of the cortical processing of anj-rectal sensation using functional MRI. Brain 2001;124:361–68.
41. Holtmann G, Siffert W, Haag S, et al. G-protein beta3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004;126:971–79.
42. Isgar B, Harman M, Kaye MD, et al. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983;24:190–92.
43. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systemic review of randomized, controlled trials. Ann Intern Med 2000;133:136–37.
44. Kim HJ, Camilleri M, Carlson PJ, et al. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004;53:829–37.
45. Kruis W, Thieme CH, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984;87:1–7.
46. Lancaster-Smith MJ, Prout BJ, Pinto T, et al. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity. Acta Psychiatr Scand 1982;66:33–41.
47. Levy RL, Whitehead WE, Von Korff MR, et al. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000; 95:451–56.
48. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001;96:3122–29.
49. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292:852–58.
50. Locke GR, Pemberton JH, Phillips SF. AGA technical review on constipation. Gastroenterology 2000;119:1766–78.
51. Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003;98:600–07.
52. Longstreth GF. Definition and classification of IBS: current consensus and controversies. Gastroenterol Clin North Am 2005;34:173–87.
53. Longstreth GF, Drossman DA. Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs. Clin Gastroenterol Hepatol 2005; 3:397–400.
54. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653–54.
55. Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut 2000;47:861–69.
56. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994;107:271–93.
57. Mearin F, Balboa A, Badia X, et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol 2003;15:165–72.
58. Mertz H, Fass R, Kodner A, et al. Effect of amitryptiline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998;93:160–65.
59. Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000;118:842–48.
60. Morgan V, Pickens D, Shyr Y. Anxiety is associated with increased anterior cingulated but not thalamic activation during rectal pain in IBS and controls. Gastroenterology 2001;120(Suppl. 1):3850.
61. Naliboff BD, Derbyshire SWG, Munakata J, et al. Cerebral activation in irritable bowel syndrome patients and control subjects during rectosigmoid stimulation. Psychosom Med 2001; 63:365–75.
62. Niaz SK, Sandrasegaran K, Renny FH, et al. Postinfective diarrhea and bile acid malabsorption. J R Coll Psysicians Lond 1997;31:53–56.
63. O’Donnell LJD, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. Br Med J 1990;300:439–40.
64. O’Leary C, Wieneke P, Buckley S, et al. Celiac disease and irritable bowel-type symptoms. Am J Gastroenterol 2002;6:1463–67.
65. Onghena P, Houdenhove BV. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992;49:205–19.
66. Parker TJ, Woolner JT, Prevost AT, et al. Irritable bowel syndrome: is the search for lactose intolerance justified? Eur J Gastroenterol Hepatol 2001;13:219–25.
67. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004;127:1592–22.
68. Powell R. On certain painful afflictions of the intestinal canal. Med Trans Royal Coll Phys 1818;6:106–17.
69. Quigley EMM, Hasler WL, Parkman HP. AGA technical review on nausea and vomiting. Gastroenterol 2001;120:263–86.
70. Quigley EMM. Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chinese J Dig Dis 2005;6:122–32.
71. Ragnarsson G, Bodemar G. Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients; description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol 1998; 10:415–21.
72. Ragnarsson G, Bodemar G. Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples. Scand J Gastroenterol 1999;34:993–1000.
73. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005;100:936–71.
74. Read M, Read NW, Barber DC, et al. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci 1982;27:807–14.
75. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001;76:511–27.
76. Ringel Y, Drossman DA, Leserman J, et al. Association of anterior cingulated cortex (ACC) activation with psychosocial distress and pain reports. Gastroenterology 2003;124(4):A-97.
77. Saito YA, Schoenfeld P, Locke GRI. The epidemiology of irritable bowel syndrome in North America: a systemic review. Am J Gastroenterol 2002;—97:1910-1915.
78. Skoog SM, Bharucha AE. Dietary fructose and gastrointestinal symptoms: a review. Am J Gastroenterol 2004;99:2046–50.
79. Snook J, Shepherd AH. Bran supplementation in the treatment of the irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:511–14.
80. Sperber AD, Carmel S, Atzmon Y, et al. Use of the functional bowel disorder severity index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia. Am J Gastroenterol 2000;95:995–98.
81. Spiegel BM, Derosa VP, Gralnek IM, et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004;126: 1721–32.
82. Spiller RC. Post infectious irritable bowel syndrome. Gastroenterology 2003;124:1662–71.
83. Stam R, Ekkelenkamp K, Frankhuijnzeel AW, et al. Long-lasting changes in central nervous system responsivity to colonic distension after stress in rats. Gastroenterology 2002; 123:1216–25.
84. Su X, Gebhart GF. Effects of tricyclic antidepressants on mechanosensitivity pelvic nerve afferent fibers innervating the rat colon. Pain 1998;76:105–14.
85. Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995;333:1–4.
86. Tillisch K, Labus JS, Naliboff BD, et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005;100:896–904.
87. Thompson WG. Proctalgia fugax. Dig Dis Sci 1981;26:1121–24.
88. Thompson WG. Gut reactions. New York; Plenum, 1989.
89. Thompson WG, Dotevall G, Drossman DA, et al. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989;2:92–95.
90. Thompson WG, Creed FN, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992;5:75–91.
91. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. In: Drossman D.A., Corazziari E., Talley N.J. et al. (eds). The functional gastrointestinal disorders. 2nd ed. Washington: Degnon, 2000.
92. Thompson WG, Heaton KW. Irritable bowel syndrome. 2nd ed. Abbington, Oxford: Health Press, 2003.
93. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disease and functional abdominal pain. Gut 1999;45:43–47.
94. Verne GN, Himes NC, Robinson ME, et al. Central representation of cutaneous and visceral pain in irritable bowel syndrome. Gastroenterology 2001;120(Suppl. 1):A713.
95. Walters B, Vanner S. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005; 100: 1566–70.
96. Whitehead WE, Crowell MD, Bosmajian L, et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology 1990; 98:336–40.
97. Whitehead WE, Paulsson O, Jones KR. Systematic review of the comorbidity or irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122:1140–56.
98. Whitehead WE, Bassotti G, Palsson O, et al. Factor analysis of bowel symptoms in US and Italian populations. Dig Liver Dis 2003; 35:774–83.
99. Wilson A, Longstreth G, Knight K, et al. Quality of life in managed care patients with irritable bowel syndrome. Manage Care Interface 2004;17:24–28.
100. Yeo A, Boyd P, Lumsden S, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhea predominant irritable bowel syndrome in women. Gut 2004;53:1452–58.
101. Mueller-Leissner S, Tytgat GN, Paulo LG, et al. Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther 2006;23:1741–48.
102. Tytgat GN. Hyoscine butylbromide. A review of its use in treatment of abdominal cramping and pain. Drugs 2007;67(9):1343–57.
103. Ishii M, Kurachi Y. Muscarinic acetylcholine receptors. Curr Pharmaceut Des 2006; 12(28):3573–81.